Literature DB >> 19112738

The persistence of red cell alloantibodies.

Roberto Reverberi1.   

Abstract

BACKGROUND: Red cell alloantibodies may disappear over time and cause a delayed haemolytic reaction if their past existence is not known before a transfusion. Only few quantitative data have already been presented on this topic. STUDY DESIGN AND METHODS: We retrieved the records of alloantibodies detected between 1989 and 2008 in our institution. All warm-reacting alloantibodies were included, with the exception of ABO antibodies, anti-D in women of childbearing age (it was impossible to rule out Rh prophylaxis) and antibodies produced by transfusion-dependent beta-thalassaemia patients (their transfusion history was too unusual).
RESULTS: We found 673 antibodies, produced by 525 patients, which had been tested again after the initial detection. The median follow-up was 319 days. The overall rate of non-persistence was 37%, corresponding to 251 antibodies, produced by 216 patients. Non-persistent antibodies were associated with a longer follow-up (409 vs. 236 days; p=0.012), more tests after detection (2 vs. 1; p<0.001), and a lower maximum score (2+ vs. 3+; p<0.001). Antibody specificity, too, influenced the duration of persistence. Among common antibodies, anti-D was the most long-lived (14% non-persistence); anti-Jka the most short-lived (43% non-persistence). Antibodies detected in the second decade of the study were less persistent (p<0.001). They were also weaker (maximum score: 2+ vs. 3+; p<0.001). This probably reflects the increased sensitivity of the screening tests over the course of time. Age, sex and whether the patient had produced multiple alloantibodies were not significant covariates. A minority of non-persistent antibodies (33/251, 13%) were detected again after a negative result (intermittently-detected antibodies). They had a longer follow-up (885 vs. 341 days; p=0.002), more tests after detection (5 vs. 2; p<0.001), and a higher maximum score (3+ vs. 2+; p=0.001).
CONCLUSIONS: Red cell antibodies commonly disappear. To avoid delayed haemolytic reactions, it is necessary to rely on previous records, which should be readily available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19112738      PMCID: PMC2626905          DOI: 10.2450/2008.0021-08

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  10 in total

1.  Prevention and diagnosis of delayed haemolytic transfusion reactions.

Authors:  C P Engelfriet; H W Reesink; R Fontão-Wendel; A Lazar; R A Cardoso; S Olyntho; R Achkar; S Wendel; M Pisacka; E Taaning; T Koski; J Matilainen; V Kretschmer; R Karger; C Politis; P Katsea; V Malamou; G Aprili; P Piccoli; G Gandini; M Franchini; H Schonewille; A Brand; B G Solheim; O Flesland; H Seyfried; B Michalewska; M Letowska; J-D Tissot; C Milkins; S Knowles; M DeSilva; M Contreras; D Stainsby; M R Combs; R S Arney; M J Telen
Journal:  Vox Sang       Date:  2006-11       Impact factor: 2.144

2.  Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.

Authors:  M Aickin; H Gensler
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

3.  Loss of red cell alloantibodies over time.

Authors:  G Ramsey; P Larson
Journal:  Transfusion       Date:  1988 Mar-Apr       Impact factor: 3.157

4.  Cyclical variations in anti-Rh titer detected by automatic quantitative hemagglutination.

Authors:  P Rubinstein
Journal:  Vox Sang       Date:  1972-12       Impact factor: 2.144

5.  Long persistence of rhesus antibodies.

Authors:  H E Hutchison; W McLennan
Journal:  Vox Sang       Date:  1966 Jul-Aug       Impact factor: 2.144

6.  The persistence of blood group antibodies.

Authors:  C P Engelfriet; M A Overbeeke
Journal:  Transfusion       Date:  1994-02       Impact factor: 3.157

7.  Long-term follow-up testing of red cell alloantibodies.

Authors:  G Ramsey; S J Smietana
Journal:  Transfusion       Date:  1994-02       Impact factor: 3.157

8.  Case report of an anti-Jk b persisting for sixteen years.

Authors:  M T Cox; A McMican; N Blumberg
Journal:  Transfusion       Date:  1983 Jul-Aug       Impact factor: 3.157

9.  Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease.

Authors:  W F Rosse; D Gallagher; T R Kinney; O Castro; H Dosik; J Moohr; W Wang; P S Levy
Journal:  Blood       Date:  1990-10-01       Impact factor: 22.113

10.  RBC antibody persistence.

Authors:  H Schonewille; H L Haak; A M van Zijl
Journal:  Transfusion       Date:  2000-09       Impact factor: 3.157

  10 in total
  6 in total

1.  A rewarding fresh look at routine blood group data.

Authors:  Willy A Flegel
Journal:  Blood Transfus       Date:  2008-10       Impact factor: 3.443

2.  Red cell allo- and autoimmunisation in transfused sickle cell and cancer patients in Kenyatta National Hospital, Nairobi, Kenya.

Authors:  Caroline Mangare; Amos Mbugua; Peter Maturi; Jamila Rajab; Rainer Blasczyk; Hans-Gert Heuft
Journal:  Afr J Lab Med       Date:  2015-09-25

3.  A Conceptual Framework for Optimizing Blood Matching Strategies: Balancing Patient Complications Against Total Costs Incurred.

Authors:  Joost H J van Sambeeck; Puck D de Wit; Jessie Luken; Barbera Veldhuisen; Katja van den Hurk; Anne van Dongen; Maria M W Koopman; Marian G J van Kraaij; C Ellen van der Schoot; Henk Schonewille; Wim L A M de Kort; Mart P Janssen
Journal:  Front Med (Lausanne)       Date:  2018-07-25

4.  A study of red blood cell alloimmunization and autoimmunization among 200 multitransfused Egyptian β thalassemia patients.

Authors:  Amal El-Beshlawy; Alshymaa Ahmed Salama; Mohamed Roshdy El-Masry; Noha M El Husseiny; Asmaa M Abdelhameed
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

5.  Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial.

Authors:  Rahul Vishwanath Mayekar; Gopalkrishna Vinayak Paradkar; Archana Anilkumar Bhosale; Rekha Sachan; Sumalatha Beeram; Ashok Ramachandra Anand; Shuchita Ramesh Mundle; Yamini Trivedi; Rashmi Md; Kiran Pandharinath Patole; Pradip Wamanrao Sambarey; Gautam Vinod Daftary; James John; Ganesh Harishchandra Divekar
Journal:  Obstet Gynecol Sci       Date:  2020-04-21

6.  Comparison of two column agglutination tests for red blood cell antibody testing.

Authors:  Jonas Sawierucha; Marion Posset; Viola Hähnel; Christian L Johnson; James A Hutchinson; Norbert Ahrens
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.